Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
about
Dietary interventions for mineral and bone disorder in people with chronic kidney diseaseDietary interventions for mineral and bone disorder in people with chronic kidney diseasePhosphate binders for preventing and treating bone disease in chronic kidney disease patientsHyperphosphatemia Management in Patients with Chronic Kidney DiseaseArterial calcification in chronic kidney disease: key roles for calcium and phosphateHyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherencePhosphate control in end-stage renal disease: barriers and opportunitiesIs there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisGaps between Global Guidelines and Local Practices in CKD-MBDRacial Differences in Association of Serum Calcium with Mortality and Incident Cardio- and Cerebrovascular Events.Association of pretransplant serum phosphorus with posttransplant outcomes.Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKDOutcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney diseaseEffect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study.Outcomes of chronic dialysis patients admitted to the intensive care unit.Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification.What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach.Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients.Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population - a nationwide, population-based study 1991 - 2009The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4The Effect of Diet on the Survival of Patients with Chronic Kidney Disease.Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patientsAssociation of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabilityPhosphorus is associated with coronary artery disease in patients with preserved renal functionFibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trialIs serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.
P2860
Q24187142-C15D3AA1-35CD-4C01-BBE2-031CA65C0AF1Q24201392-5D0AA696-3FFF-46C8-9B32-A2B139B0F7EEQ24234036-0A0ACA31-1DAB-4357-AB3D-7564F909F8B1Q26743842-122615D2-BB11-412C-953D-4D8C2CB6F526Q26827655-74536FE9-EACB-4BCB-95E5-0BDCBAE6861AQ26830013-21592F82-56B1-4D22-943E-915AFCE03C18Q26853372-827E1F88-71F9-4D9F-8982-ED5F9189D640Q27011288-BC7FAD13-0ED6-4207-80FB-EEEE650C717AQ27022356-8AD22403-4D4F-4F60-B399-C5FCDB816109Q30275940-3DDEC6FA-6D12-4EB7-96D3-31C7862DB2E9Q30424192-73CAE902-1277-4799-9010-4FB3B166E364Q30429870-3C7F44BD-1BE8-42D2-A715-16D7ED7888F7Q30433029-E9E6699C-57D6-4832-95D5-4972D53DDEEBQ30976543-59194915-8895-4FF8-916A-DA2254CA074BQ33432308-F04F138D-3DAB-45D1-9833-48213D3ABEFFQ33454103-7D8C6541-3EC8-4FC6-AED8-D7123A3D5D63Q33561697-3F0402C3-CE0E-47E4-A6E6-605E8EF1F628Q33562186-DDC7AA98-6D46-4CA4-834E-9D4EE34AB816Q33571829-FCB31E05-B14D-498E-942A-8CE06F103643Q33616803-8561678C-1B23-413D-8615-F97A64488E93Q33625482-2C0DEF13-EB35-419E-8FAE-F9C2C0CB8AF7Q33671574-9BBFB9B0-620F-4B27-A013-FE3AF2327224Q33698118-C9C8291F-9590-47AC-9B5E-050CAFC12687Q33702417-6D6698DB-5E62-4F56-8158-9AB1209DDCBDQ33715785-16131051-3D97-4B91-B1F7-691D79BDFC2FQ33749490-F3B0DE7C-E772-4ABE-9AD4-2BF12AED2507Q33873467-D6677D22-0BBB-4F80-A136-99383B39F4F3Q33878430-F1D468EA-EA10-4266-95CE-4B9DFFF3B705Q33944788-58375783-120E-49CB-A49D-5EC90A78A0FFQ34008136-F8F52054-DB49-435B-A5B5-1F7326026285Q34027561-B61685A0-E77C-4C33-9232-28090DD6DEB9Q34037021-CFE2E66B-8A83-4396-8BB7-12049F4F3DB0Q34116591-11E93AAA-F92D-4FFE-9CAC-60B37FBE7BE1Q34135288-F28946B1-0C20-411F-B9F4-394B7057B13BQ34213692-47905DFC-9034-4C55-A92A-FD01C5A3955AQ34271082-82B8D8E5-EAEE-4F23-ACE9-2DE329150D64Q34320155-16D32BE1-0025-4F56-966D-D683079105FDQ34366087-B87F17C3-1CD4-43F3-ABCA-FD54C90FC4ACQ34403555-A182E73A-4AB2-4B1B-9255-0009D57959A5Q34406863-53B30379-BA24-487D-97E7-E185C5A64A4D
P2860
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@en
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@nl
type
label
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@en
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@nl
prefLabel
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@en
Mortality risk for dialysis pa ...... actice Patterns Study (DOPPS).
@nl
P2093
P1476
Mortality risk for dialysis pa ...... ractice Patterns Study (DOPPS)
@en
P2093
Brenda W Gillespie
Bruce M Robinson
Eric W Young
Francesca Tentori
Friedrich K Port
Jürgen Bommer
Margaret J Blayney
Peter G Kerr
Ronald L Pisoni
Tadao Akizawa
P304
P356
10.1053/J.AJKD.2008.03.020
P577
2008-06-02T00:00:00Z